Cited by 108Pancreatic function and diabetesGlycogen Storage Diseases and MyoclonusMetabolism, Diabetes, and Cancer

Insights into the Structure and Regulation of Glucokinase from a Novel Mutation (V62M), Which Causes Maturity-onset Diabetes of the Young

Open access
Gloyn, Anna L., Odili, Stella, Zelent, Dorothy, Buettger, Carol, Castleden, Harriet A.J., Steele, Anna M., Stride, Amanda, Shiota, Chyio +15 more·2005·Journal of Biological Chemistry

Abstract

Glucokinase (GCK) serves as the pancreatic glucose sensor. Heterozygous inactivating GCK mutations cause hyperglycemia, whereas activating mutations cause hypoglycemia. We studied the GCK V62M mutation identified in two families and co-segregating with hyperglycemia to understand how this mutation resulted in reduced function. Structural modeling locates the mutation close to five naturally occurring activating mutations in the allosteric activator site of the enzyme. Recombinant glutathionyl S-transferase-V62M GCK is paradoxically activated rather than inactivated due to a decreased S0.5 for glucose compared with wild type (4.88 versus 7.55 mM). The recently described pharmacological activator (RO0281675) interacts with GCK at this site. V62M GCK does not respond to RO0281675, nor does it respond to the hepatic glucokinase regulatory protein (GKRP). The enzyme is also thermally unstable, but this lability is apparently less pronounced than in the proven instability mutant E300K. Functional and structural analysis of seven amino acid substitutions at residue Val62 has identified a non-linear relationship between activation by the pharmacological activator and the van der Waals interactions energies. Smaller energies allow a hydrophobic interaction between the activator and glucokinase, whereas larger energies prohibit the ligand from fitting into the binding pocket. We conclude that V62M may cause hyperglycemia by a complex defect of GCK regulation involving instability in combination with loss of control by a putative endogenous activator and/or GKRP. This study illustrates that mutations that cause hyperglycemia are not necessarily kinetically inactivating but may exert their effects by other complex mechanisms. Elucidating such mechanisms leads to a deeper understanding of the GCK glucose sensor and the biochemistry of beta-cells and hepatocytes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m413146200

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phosphorylation of glucose by glucokinase is the rate-limiting step in insulin secretion.

    “Phosphorylation of glucose is the rate-limiting step in insulin secretion and loss-of-function mutations in GCK impair GIIS, with heterozygous mutations leading to maturity–onset-diabetes-of-the-young (MODY) and homozygous mutations to neonatal diabetes (214).”

    From Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men (2018) · cites this paper as [214]

    The introductory passage (page unavailable) calls glucokinase the pancreatic β-cell glucose sensor and says its kinetics let β-cells change glucose phosphorylation rates across physiological glucose concentrations. It also links inactivating GCK mutations to MODY, and the figure caption identifies the affected family members as heterozygous. The copy does not establish that phosphorylation is the rate-limiting step in insulin secretion or support the sentence’s claim about homozygous mutations causing neonatal diabetes. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Loss-of-function mutations in GCK impair GIIS, with heterozygous mutations leading to MODY and homozygous mutations to neonatal diabetes.

    “Phosphorylation of glucose is the rate-limiting step in insulin secretion and loss-of-function mutations in GCK impair GIIS, with heterozygous mutations leading to maturity–onset-diabetes-of-the-young (MODY) and homozygous mutations to neonatal diabetes (214).”

    From Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men (2018) · cites this paper as [214]

    The introductory passages (page unavailable) identify GCK as the pancreatic glucose sensor, say it regulates insulin secretion, and state that inactivating GCK mutations cause MODY. The Results report a heterozygous V62M mutation co-segregating with hyperglycemia. Our copy does not state that homozygous GCK mutations cause neonatal diabetes or explicitly describe glucose phosphorylation as rate-limiting. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 3

  1. Gloyn, A., Odili, S., Buettger, C., Njolstad, P. R., Shiota, C., Magnuson, M., and Matschinsky, F. (2004) in Glucokinase and Glycemic Diseases: From the Basics to Novel Therapeutics (Matschinsky, F. M., and Magnuson, M. A., eds) Vol. 16, pp. 92-109, Karger, Basel, Switzerland
  2. Stoffel, M., Froguel, P., Takeda, J., Zouali, H., Vionnet, N., Nishi, S., Weber, I. T., Harrison, R. W., Pilkis, S. J., Lesage, S., Vaxillaire, M., Velho, G., Sun, F., Iris, F., Passa, P., Cohen, D., and Bell, G. I. (1992) Proc. Natl. Acad. Sci.
  3. Sian Ellard, Andrew T. Hattersley and Franz M. Matschinsky Taub, Veiga-da-Cunha, Fabrizio Barbetti, Pete Dunten, Yi Han, Joseph Grimsby, Rebecca Giuseppe d'Annunzio, Charles A. Stanley, Jae Kwagh, Emile van Schaftingen, Maria Anna M. Steele, Amanda Stride, Chyio Shiota, Mark A. Magnuson, Renata Lorini, Anna L. Gloyn, Stella Odili, Dorothy Zelent, Carol Buettger, Harriet A. J. Castleden, (V62M), Which Causes Maturity-onset Diabetes of the Young Insights into the Structure and Regulation of Glucokinase from a Novel Mutation doi: 10.1074/jbc.M413146200 originally published online January 25, 2005 2005, 280:14105-14113.

Cited by

Sorted by citations

Authors
Gloyn, A. L., Odili, S., Zelent, D., Buettger, C., Castleden, H. A. J., Steele, A. M., Stride, A., Shiota, C., Magnuson, M. A., Lorini, R., d'Annunzio, G., Stanley, C. A., Kwagh, J., van Schaftingen, E., Veiga-da-Cunha, M., Barbetti, F., Dunten, P., Han, Y., Grimsby, J., Taub, R., Ellard, S., Hattersley, A. T., & Matschinsky, F. M.
Affiliations
  • University of Exeter (GB)
  • University of Pennsylvania (US)
  • Vanderbilt University (US)
  • Istituto Giannina Gaslini (IT)
  • Children's Hospital of Philadelphia (US)
  • Bambino Gesù Children's Hospital (IT)
Corresponding author
Matschinsky, Franz M.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2005-04
Volume
280
Issue
14
Pages
14105-14113
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2168364512
Cited by
108
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 4 · 2012: 10
FWCI
7.89
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by)
Funders
  • National Institutes of Health (5r01dk053013-03)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK53013, DK-22122)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Rheumatology › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
glucokinase, maturity-onset diabetes of the young, hyperglycemia, glutathione S-transferase, GCKR, protein structure-function relationship, beta-cell function, hepatocytes
MeSH terms
Animals, Binding Sites, Carrier Proteins, Child, Diabetes Mellitus, Type 2, DNA Mutational Analysis, Enzyme Activation, Enzyme Stability, Female, Glucokinase, Glucose, Humans, Hyperglycemia, Infant, Newborn, Male, Models, Molecular, Pedigree, Pregnancy, Recombinant Fusion Proteins, Recombinant Proteins, Point Mutation, Protein Structure, Tertiary, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review